DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
A GLP-1 Analog for the Treatment of ALS
[Technical Report, Annual Report]
JOHNS HOPKINS UNIV BALTIMORE MD
Pagination or Media Count:
The involvement of neuroinflammation manifested by activated microglia and astrocytes in ALS is supported by a wealth of clinical and molecular evidence. In addition to producing neurotoxic cytokines, activated microglia also induce differentiation of astroglial cells into neurotoxic A1 astrocytes - direct mediators of neuronal cell death, including possibly in ALS. Therefore, development of agents that could selectively inhibit the microglial activation and A1 astrocyte formation without off-target toxicity could have profound therapeutic potential since they could be used to treat a variety of neurologic disorders for which there currently are no disease-modifying therapies. NLY01 is a GLP-1R agonist. NLY01 selectively inhibits microglial activation, and blocks induction of cytokines and A1 astrocyte formation thus, providing neuroprotection. The overall objective is to collect data for a FDA IND application for ALS. We propose to develop NLY01 for ALS its potential as a target using both ALS animal and human ALS iPSC-based models.
[A, Approved For Public Release]